Medtronic stock rating upgraded to Neutral by Goldman Sachs on new product momentum

Goldman Sachs upgraded Medtronic from Sell to Neutral and raised its price target to $111 after the company reported stronger-than-expected Q2 FY2026 results (adjusted EPS $1.36 vs. $1.31 est.; revenue $9.0B vs. $8.87B), citing clear execution, product momentum and two consecutive quarters of increased R&D and SG&A reinvestment that could support higher top-line growth. The upgrade, echoed by Evercore ISI raising its target to $115 (Outperform) and analyst targets ranging $92–$120, reflects faster-than-modeled organic revenue improvement and improved sentiment—shares have risen about 25% since late May—though the stock trades at roughly a 28x P/E and appears slightly rich versus InvestingPro fair value. For investors, the key implications are that reinvestment and growth in areas like atrial fibrillation/pulsed-field ablation are driving a re-rating, but valuation and sustainability of the revenue acceleration warrant monitoring.

Analysis

Goldman Sachs upgraded Medtronic from Sell to Neutral and raised its price target to $111 after the company reported stronger-than-expected Q2 FY2026 results: adjusted EPS $1.36 versus $1.31 consensus and revenue $9.0 billion versus $8.87 billion estimates. Evercore ISI also raised its target to $115 from $107 and kept an Outperform, while analyst targets range $92–$120 and consensus leans Buy; the shares trade near a 52-week high of $102.48 and the company has paid dividends for 49 consecutive years.

Goldman cited two consecutive quarters of increased R&D and SG&A reinvestment and described clear execution and product momentum as the rationale for a more positive outlook, implying reinvestment could support higher top-line growth. Evercore highlighted growth in atrial fibrillation solutions, driven by pulsed-field ablation, as a specific growth vector that helped drive the revenue beat.

Valuation and sustainability are the main risks: Medtronic trades at a P/E of 28.03 with 4.98% LTM revenue growth and appears slightly rich versus InvestingPro fair value, and shares have risen ~25% since May 30, 2024 while the S&P gained ~26% in the same period. Investors should watch whether elevated reinvestment converts to durable organic revenue acceleration and whether margins/EPS can hold up as R&D and SG&A remain elevated.

Key Decisions for Investors

• Consider adding to positions on modest pullbacks if upcoming quarters confirm continued organic revenue acceleration, given product momentum and upgraded analyst targets
• Monitor next two quarters' organic revenue growth, R&D/SG&A reinvestment cadence, and margin trajectory as the primary catalysts that will validate the re-rating
• Limit position size or hedge exposure while valuation (P/E ~28) remains slightly above InvestingPro fair value and the stock trades near its 52‑week high
• Trim or reallocate if reinvestment fails to produce sustained EPS improvement or if analyst sentiment and price targets reverse